Introduction
Chronic visceral pain, altered intestinal motility and bladder dysfunction remain poorly managed symptoms of functional and inflammatory disorders of the gastrointestinal and urinary tracts. A lack of suitable treatments for these disorders is a major contributing factor to their debilitating nature and the large socio-economic cost accrued by patients, their families and society (NIH, 2009; Gaskin & Richard, 2012; Enck et al. 2016) . Conventional analgesics, such as opioids and non-steroidal antiinflammatory drugs (NSAIDs), are unsuitable for treating chronic pain originating in the gastrointestinal and lower urinary tract, as they are associated with severe side effects. This includes tolerance, a lack of efficacy and importantly for some inflammatory gastrointestinal disorders the potential to exacerbate the disease (Sikandar & Dickenson, 2012; Farrell et al. 2014) . The colon, rectum and bladder are innervated by specialised sensory afferents travelling via the splanchnic and pelvic nerves that terminate within the dorsal horn of the thoracolumbar and lumbosacral spinal cord, respectively (Brierley et al. 2004; Harrington et al. 2012; Brierley & Linden, 2014) . These neurons detect both non-noxious physiological stimuli, including muscle stretch during organ distension, and noxious mechanical and chemical stimuli such as bloating, intense distension/contraction, or the presence of inflammatory mediators (Brierley & Linden, 2014; Brierley, 2016) . To encode for such wide-ranging stimuli, visceral organs rely on an array of stimuli-activated primary 'sentinel' transducers, including transient receptor potential (TRP) channels, acid-sensing ion channels (ASIC), mechanosensitive two-pore domain K (K2P) channels and Piezo channels (Grundy, 2002; Brierley, 2010; Christianson & Davis, 2010; La & Gebhart, 2011; Brierley, 2016; Alcaino et al. 2017) . Furthermore, primary transducers and ion channels involved in sensory signalling can be modulated and controlled by G-protein coupled receptors (GPCRs) and regulators of GPCR signalling proteins, in response to endogenous mediators (Geppetti et al. 2015; Salaga et al. 2016) .
Voltage-gated sodium (Na V ) channels are secondary in the neuronal response to non-noxious or noxious stimuli. They perform the crucial role of regulating neuronal excitability and the key function of amplifying cation influx generated by the primary transducers to generate and propagate action potentials (Catterall, 2012; . Voltage-gated potassium (K V ) channels repolarise the membrane potential following Na + influx and modulate firing frequency, and have been reported to contribute to visceral hypersensitivity in peripheral neurons in animal models (Hirano et al. 2007; Qian et al. 2009; Luo et al. 2011; Du & Gamper, 2013) ; however, this family of ion channels is not covered within the scope of this review.
The Na V channel family contains nine isoforms (Na V 1.1-Na V 1.9), which are encoded by nine SCN genes (SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, SCN11A) . Functionally, these channels are historically categorised as either tetrodotoxin-sensitive (TTX-S: Na V 1.1-Na V 1.4, Na V 1.6 and Na V 1.7), or tetrodotoxin-resistant (TTX-R: Na V 1.5, Na V 1.8 and Na V 1.9). Anatomically, these channels display wide and diverse expression patterns across neuronal and smooth muscle cells throughout the body (Table 1) , as well as cells of the immune system (including macrophages and mast cells) where they are involved in migration and phagocytosis (Bradding et al. 2003; Roselli et al. 2006; Carrithers et al. 2011; Black & Waxman, 2013) . Na V 1.1, Na V 1.2, Na V 1.3 and Na V 1.6 are traditionally considered to be the predominant isoforms expressed in the brain and spinal cord, whilst Na V 1.7, Na V 1.8 (Beckh et al. 1989; Westenbroek et al. 1989) Mouse CNS Cerebral cortex, cerebellum, hippocampus, thalamus, central grey,
pons, medulla
Fimbria, corpus callosum (Duflocq et al. 2008) Human PNS L3-L5 (Chang et al. 2018) Rat PNS L4-L5; L5 (Black et al. 1996; Fukuoka et al. 2008; Wang et al. 2011) Mouse PNS Colonic neurons in T10-L1 and L5-S1; T10-L1 L3-L6 dorsal and ventral roots (Duflocq et al. 2008; Osteen et al. 2016; Hockley et al. 2017) Human ENS Colonic myenteric plexus (Hetz et al. 2014) Guinea pig (Beckh et al. 1989; Westenbroek et al. 1989) Human PNS L3-L5 (Chang et al. 2018) Rat PNS L4-L5; L5 (Black et al. 1996; Fukuoka et al. 2008) Mouse PNS Colonic neurons in T10-L1 and L5-S1 (Chang et al. 2018; Hockley et al. 2017) Human ENS Colonic myenteric plexus (Hetz et al. 2014) Guinea pig (Black et al. 1996; Fukuoka et al. 2008) Mouse PNS Colonic neurons in T10-L1 and L5-S1; DRG (Chang et al. 2018; Hockley et al. 2017) Human ENS Colonic myenteric plexus (Hetz et al. 2014) Guinea pig ENS Duodenal myenteric plexus (Sage et al. 2007) (Continued) (Strege et al. 2003) Human, dog, rat Muscle Jejunal circular smooth muscle (Holm et al. 2002; Ou et al. 2002; Strege et al. 2007; Human, rat Muscle Colonic circular smooth muscle (Strege et al. 2003; Human, mouse
ENS

Muscle
Jejunal longitudinal smooth muscle Strege et al. 2007) Pig, guinea pig
Jejunal circular smooth muscle (Strege et al. 2007) Human Macrophages Macrophages (Carrithers et al. 2007 (Carrithers et al. , 2011 Black & Waxman, 2013) Na V 1.6
Human CNS Cerebral cortex, cerebellum, hypothalamus, caudate, hippocampus (Whitaker et al. 1999; GTEx Consortium et al. 2017) Rat CNS Cerebellum, hippocampus, spinal cord (white and grey matter) (Tzoumaka et al. 2000) Mouse CNS Spinal cord white and grey matter (Duflocq et al. 2008) Human PNS L3-L5 (Chang et al. 2018) Rat PNS L4-L5; L5 (Tzoumaka et al. 2000; Fukuoka et al. 2008) Mouse PNS L3-L6 dorsal and ventral roots; DRG (Duflocq et al. 2008; Chang et al. 2018) Mouse PNS Colonic neurons in T10-L1 and L5-S1; T10-L1; T9-T13; L6 (King et al. 2009; Feng et al. 2015; Hockley et al. 2017; Inserra et al. 2017) Human ENS Colonic myenteric plexus (Hetz et al. 2014) Guinea pig ENS Duodenal myenteric plexus (Sage et al. 2007) (Continued) (Flegel et al. 2015; Chang et al. 2018) Rat PNS L5 (Fukuoka et al. 2008) Mouse PNS Colonic neurons in T10-L1 and L5-S1; T10-L1; L6 (Feng et al. 2015; Hockley et al. 2017; Inserra et al. 2017) Human ENS Colonic myenteric plexus (Hetz et al. 2014) Guinea pig ENS Duodenal myenteric plexus (Sage et al. 2007 )
Human CNS Brain (Flegel et al. 2015; GTEx Consortium et al. 2017) Human PNS L3-L5; DRG (Flegel et al. 2015; Chang et al. 2018) Rat PNS Colonic neurons T13-L2 (Hu et al. 2013a (Hu et al. , 2016 Lin et al. 2017) Mouse PNS Colonic neurons in T10-L1 and L5-S1; T10-L1; T9-T13; T9-L1; L6 (Beyak et al. 2004; Hillsley et al. 2006; King et al. 2009; Feng et al. 2015; Hockley et al. 2017; Inserra et al. 2017 and Na V 1.9 are preferentially expressed in the peripheral nervous system (PNS). Na V 1.4 is found predominantly within skeletal muscle and Na V 1.5 is the major isoform in cardiac myocytes (Catterall et al. 2005) . Furthermore, Na V channels are regulated by a range of enzymes and structural proteins, including auxiliary β-subunits (β1, β1 B , β2, β3, β4) (Qin et al. 2003; Tseng et al. 2007 ), kinases and ubiquitin-protein ligases (Feng et al. 2012; Savio-Galimberti et al. 2012; Laedermann et al. 2015) , which collectively regulate Na V channel biophysical properties and expression. Recently, numerous studies have reported Na V isoform channelopathies, including for Na V 1.7 (SCN9A), Na V 1.8 (SCN10A) and Na V 1.9 (SCN11A) as the primary cause of increased pain or loss of pain phenotypes in humans (Yang et al. 2004; Cox et al. 2006; Fertleman et al. 2006; Klein et al. 2013; Leipold et al. 2013; Huang et al. 2014 Huang et al. , 2017 Waxman et al. 2014; Dib-Hajj et al. 2015; Han et al. 2015) . Pharmacological modulation of Na V channels supports these genetic observations, including the finding that activation of all Na V channels by Pacific ciguatoxin 1 (P-CTX-1) or veratridine due to accidental consumption manifests as acute and severe gastrointestinal disturbances associated with abdominal pain in humans (Schep et al. 2006; Stewart et al. 2010) . Intracolonic administration of purified P-CTX-1 also causes pain behaviour in mice (Inserra et al. 2017) . On the other hand, TTX (which blocks Na V 1.1-Na V 1.4, Na V 1.6 and Na V 1.7) poisoning in humans is associated with paralysis rather than pain (Lago et al. 2015) . Whilst potentially fatal upon consumption, administration of Na V -selective agents such as TTX and neosaxitoxin has been shown to decrease pain responses in a range of pain modalities including visceral pain in humans (Hagen et al. 2011 (Hagen et al. , 2017 Manriquez et al. 2015) and rodents (Marcil et al. 2006; Gonzalez-Cano et al. 2017) . Similarly, intrarectal administration of lidocaine (lignocaine) in irritable bowel syndrome (IBS) patients reduces rectal sensitivity and abdominal pain, suggesting Na V channels and activation of peripheral afferent endings in the colon play key roles in the pathogenesis of chronic visceral pain in IBS patients (Verne et al. 2005) .
Human genetic studies have triggered widespread investigation into the therapeutic potential of Na V channels in the treatment of acute and chronic pain and also prompted studies to identify the wider roles of these channels throughout the body. It is also clear from most studies utilising inflammatory, nematode or bacterial models that gut-and bladder-innervating neurons become hyperexcitable after the initial insult, which involves changes in TTX-R and TTX-S Na V currents, amongst others. This is apparent in neurons innervating the stomach (Gebhart et al. 2002; Bielefeldt et al. 2002a, b; Dang et al. 2004) , small intestine (Moore et al. 2002; Stewart et al. 2003; Hillsley et al. 2006; Keating et al. 2008) , the colon (Beyak et al. 2004; Ibeakanma et al. 2009; King et al. 2009 ) and the bladder (Yoshimura & deGroat, 1997) . This review presents recent evidence on the specific roles of Na V 1.1-Na V 1.9 in transmitting sensation and nociception from the distal gut and bladder in healthy and pathological states. Na V 1.1 Na V 1.1 is predominantly expressed in cell bodies, axon initial segments and at the nodes of Ranvier in the central nervous system (CNS) (Westenbroek et al. 1989; Duflocq et al. 2008; Carithers et al. 2015; Uhlen et al. 2015; GTEx Consortium et al. 2017) . It is also expressed in human, rat and mouse PNS (Fukuoka et al. 2008; Wang et al. 2011; Osteen et al. 2016; Chang et al. 2018) , and in human, but not guinea pig, myenteric plexus (Sage et al. 2007; Hetz et al. 2014) (Table 1 ). In thoracolumbar (T10-L1) and lumbar (L5) dorsal root ganglia (DRG) neurons, which contain the cell bodies of sensory neurons innervating the colon, rectum, bladder and skin, Na V 1.1 is expressed in 15-35% of all neurons. Expression is predominantly in Tropomyosin-related kinase C (TrkC)-and Tropomyosin-related kinase A (TrkA)-expressing myelinated A-fibres of medium to large diameter and nearly absent in C-fibre small diameter neurons innervating the skin (Fukuoka et al. 2008; Wang et al. 2011; Osteen et al. 2016) . However, Na V 1.1 mRNA transcript is detected in approximately half of thoracolumbar (T10-L1) and lumbosacral (L5-S1) mouse DRG neurons innervating the colon (Osteen et al. 2016; Hockley et al. 2017) . As colonic afferents are predominantly peptidergic C-fibres, there are clearly key differences in the populations of afferent neurons expressing Na V 1.1 when comparing between the colon and the skin. In colon-innervating DRG neurons, Na V 1.1 is frequently co-localised with Na V 1.2, Na V 1.3, Na V 1.6, Na V 1.7, Na V 1.8 and Na V 1.9 (Osteen et al. 2016; Hockley et al. 2017) . Functional studies of colonic afferents reveal that Na V 1.1 plays a crucial role in the signalling of mechanical pain from the colon (Osteen et al. 2016) . Application of the selective Na V 1.1 agonist, δ-theraphotoxin-Hm1a (Hm1a), enhances mechanically evoked firing in a subpopulation of high-threshold colonic nociceptors. Notably, the mechanical hypersensitivity evoked by Hm1a was blocked by incubation with the Na V 1.1/Na V 1.3 antagonist ICA-121431 (Table 2) (Osteen et al. 2016) . Furthermore, Hm1a also induces hyperexcitability of isolated colon-innervating DRG neurons from healthy control mice (Osteen et al. 2016) . Notably, the percentage of colon-innervating afferents/neurons affected by Hm1a is similar to the percentage of colon-innervating DRG neurons expressing Na V 1.1, as determined by single cell PCR (Osteen et al. 2016; Hockley et al. 2017) . Importantly, colon-innervating DRG neurons isolated from mice with chronic visceral hypersensitivity (CVH) Increase in colonic nociceptor response to mechanical stimuli in a sub-population of afferents. (Osteen et al. 2016) Colonic stretch (ex vivo extracellular recordings of colorectal afferents in the pelvic nerve)
μ-conotoxin GIIIa, and μ-conotoxin PIIIa, serosal/mucosal application)
Reduced action potential firing of stretch-sensitive afferent response (Feng et al. 2015) Colonic stretch (ex vivo extracellular recordings of colorectal afferents in the pelvic nerve) -ProTxII (Na v 1.7 antagonist, serosal/mucosal application)
No difference in stretch-sensitive afferent response (Feng et al. 2015) Ciguatoxin (pan-Na v agonist) (intracolonic)
Increased pain behavioural response (Inserra et al. 2017) Colonic incubation with A-803467 (Na v 1.8 antagonist) (ex vivo extracellular recordings of colorectal nociceptors), followed by ciguatoxin (Yoshimura & deGroat, 1997) show significantly enhanced responsiveness to Hm1a compared to healthy control mice, suggesting that Na V 1.1 may be essential for the development and maintenance of chronic visceral pain conditions (Osteen et al. 2016) . As such, antagonism of Na V 1.1 may be a future target for the treatment of disorders accompanied by chronic visceral pain originating from the colon. There are currently no reports on the expression profile or function of Na V 1.1 in the bladder or bladder-innervating sensory neurons.
Na V 1.2 is extensively expressed in the CNS (Jarnot & Corbett, 2006) but has also been detected at low levels in small-diameter DRG neurons (Black et al. 1996; Fukuoka et al. 2008; Chang et al. 2018) . Conversely, in colon-innervating DRG neurons of the mouse, Na V 1.2 mRNA transcript is present in 69% of thoracolumbar (T10-L1) neurons and at a similar level in lumbosacral (L5-S1) neurons (Hockley et al. 2017) (Table 1) . Despite this mRNA expression, there is currently no functional data to support a role for Na V 1.2 in colonic sensory signalling or pain. Similarly, there are currently no reports on the expression profile or function of Na V 1.2 in the bladder or bladder-innervating sensory neurons.
Na V 1.3 is highly expressed in sensory neurons during embryogenesis in rats, but its expression traditionally subsides in fully developed neurons (Beckh et al. 1989) . The major body of Na V 1.3 research in nociception focuses on its role in neuropathic pain, as Na V 1.3 is re-expressed following neuropathic injury in large diameter, myelinated A-fibre neurons where it may contribute to ectopic discharge and painful neuropathy (Waxman et al. 1994; Zang et al. 2010 ). However, due to the limited expression of this channel in adult tissues and lack of channelopathy-associated pain syndromes, studies investigating the role of Na V 1.3 in other pain pathways are few. In relation to the viscera, Na V 1.3 mRNA is detected in adult guinea-pig enteric nervous system (ENS) neurons (Sage et al. 2007 ), but its functional role has yet to be determined. Initial experiments indicate that Na V 1.3 expression is low in rat lumbar (L5) DRG neurons (Fukuoka et al. 2008) . However, Na V 1.3 mRNA transcripts are detected in approximately half of the colon-innervating thoracolumbar (T10-L1) and lumbosacral (L5-S1) DRG neurons in the mouse (Hockley et al. 2017) (Table 1) . More recent studies show a key role for Na V 1.3 in non-neuronal tissues, specifically within enterochromaffin cells located within the epithelium from the small and large intestine of humans and mice (Bellono et al. 2017; Strege et al. 2017a,b) . Voltage-gated sodium currents generated by Na V 1.3 likely allow enterochromaffin cells to respond to the detection of mechanical and chemical stimuli within the lumen of the intestine (Bellono et al. 2017; Strege et al. 2017b) . In contrast, expression of the other eight Na V isoforms is very low, or indeed lacking from both intestinal enterochromaffin cells and the wider population of intestinal epithelial cells (Bellono et al. 2017) . There are currently no reports on the role of Na V 1.3 in the bladder or bladder-innervating sensory neurons. Na V 1. 4 Na V 1.4 is the predominant Na V isoform in skeletal muscle (Trimmer et al. 1990 ) but is also found in human oesophageal smooth muscle tissue (Deshpande et al. 2002) . In peripheral neurons, Na V 1.4 transcripts are nearly absent in rat lumbar (L5) DRG (Fukuoka et al. 2008) and in colon-innervating mouse DRG neurons (Hockley et al. 2017) (Table 1 ). In agreement with tissue distribution, Na V 1.4 channelopathies appear to exclusively involve deficits in skeletal muscle function, and to date no involvement in colon or bladder function has been shown.
Na V 1.5
Na V 1.5 channels have been identified in circular smooth muscle of the jejunum of human, dog, rat and mouse but are absent in pig and guinea pig. Na V 1.5 is also absent from human and mouse jejunal longitudinal smooth muscle (Holm et al. 2002; Ou et al. 2002; Strege et al. 2007; ). Na V 1.5 has been found in colonic circular smooth muscle of human and rat (Strege et al. 2003) , in jejunal interstitial cells of Cajal in human (Strege et al. 2003) , and in myenteric plexuses of human and mouse (Hetz et al. 2014; Osorio et al. 2014) . Na V 1.5 in circular smooth muscle may contribute to normal intestinal motility through modulation of slow-wave activity and muscle contractility Strege et al. 2007) . These findings are supported by data showing that ranolazine, a treatment for chronic angina, is able to inhibit Na V 1.5 currents in human colonic smooth muscle cells (Neshatian et al. 2015) , which is likely to be responsible for the constipation seen during long-term ranolazine treatment (Nash & Nash, 2008) . These data strongly point towards a primary role for Na V 1.5 channels in mediating gastrointestinal motility and transit . Similarly, several loss-of-function mutations in SCN5A, the gene encoding Na V 1.5 channels, are associated with IBS and abdominal pain (Saito et al. 2009; Beyder et al. 2014; Strege et al. 2017c) . Whether this is purely a consequence of reduced gastrointestinal contractility or whether Na V 1.5 channels also play a direct role in visceral sensation remains unclear, as Na V 1.5 mRNA transcripts are expressed in 18% of thoracolumbar and 51% of lumbosacral colon-innervating DRG neurons (Hockley et al. 2017) (Table 1) . Whether this translates into channel J Physiol 596.5 expression and a functional role remains to be determined. There are currently no reports on the expression profile or function of Na V 1.5 in the bladder or bladder-innervating sensory neurons.
Na V 1.6
Na V 1.6 is extensively expressed within the CNS and PNS (Whitaker et al. 1999; Tzoumaka et al. 2000; Catterall et al. 2005; Catterall, 2012; Chang et al. 2018) , commonly located in clusters at the nodes of Ranvier (Duflocq et al. 2008) , indicating that Na V 1.6 may have a primary role in transmitting rather than initiating action potentials. In rat lumbar (L5) DRG neurons, Na V 1.6 transcripts are detected in a third of all neurons and selectively expressed in TrkCand TrkA-expressing myelinated A-fibre nociceptors (Fukuoka et al. 2008) . In colon-innervating mouse DRG neurons, Na V 1.6 mRNA transcript is present in 63-87% of thoracolumbar (T10-L1) neurons, and in 51% of lumbosacral (L5-S1) neurons (Hockley et al. 2017; Inserra et al. 2017) . Immunohistochemical and western blot analysis show that Na V 1.6 protein is present in the cell bodies of sensory neurons and on sensory afferent nerve endings innervating the distal colon and rectum in mice (Feng et al. 2015) (Table 1) . Antagonism of Na V 1.6 reduces action potential firing of stretch-sensitive colorectal afferents in vitro (Feng et al. 2015) (Table 2) . Whether these effects are altered in animal models of inflammatory or chronic visceral pain remains to be investigated. It has, however, been reported that there is no change in Na V 1.6 expression in colon-innervating DRG neurons (T9-T13) during the acute inflammatory phase of the mouse model of trinitrobenzenesulphonic acid (TNBS)-induced colitis (King et al. 2009 ). This corresponds with the phase when colorectal afferent hypersensitivity also occurs (Hughes et al. 2009 ). Activation of low-threshold stretch-sensitive afferents is essential for normal physiological function of the colon (Brierley et al. 2004; Kyloh et al. 2011 ) and Na V 1.6 appears to play a key integrative role in this process. Whether Na V 1.6 contributes to aberrant colonic afferent sensory signalling during chronic visceral hypersensitivity remains to be determined. There are currently no reports on the expression profile or function of Na V 1.6 in the bladder or bladder-innervating sensory neurons.
Na V 1.7
Na V 1.7 has become a key target of interest as several human mutations in the SCN9A gene, which encodes Na V 1.7, lead to either a loss of pain or increased pain perception (Bennett & Woods, 2014) . For example, a loss-of-function mutation of SCN9A results in a congenital insensitivity to pain (CIP) (Cox et al. 2006; Goldberg et al. 2007) , whereas gain-of-function mutations produce distinct pain syndromes, such as erythromelalgia, small-fibre neuropathy and paroxysmal extreme pain disorder (Fertleman et al. 2006 ). Na V 1.7 is extensively expressed in sensory and sympathetic neurons of the PNS, as well as ENS neurons, and is highly restricted in the CNS (Klugbauer et al. 1995; Catterall et al. 2005; Morinville et al. 2007; Sage et al. 2007; Branco et al. 2016; Chang et al. 2018) . In rat lumbar (L5) DRG neurons, Na V 1.7 transcripts are preferentially expressed in TrkA-expressing C-fibre neurons, and in a subset of A-fibre neurons (Fukuoka et al. 2008) . Robust immunolabelling of Na V 1.7 is present within the peripheral endings of sensory nerves in the skin (Black et al. 2012) .
From mouse knock-out studies, it appears that Na V 1.7 in Na V 1.8-expressing cells (Na V 1.7 Nav1.8 ) does not contribute in the development of neuropathic pain, nor noxious cold or heat detection (Nassar et al. 2004 (Nassar et al. , 2005 Minett et al. 2012 Minett et al. , 2014 Hockley et al. 2017) . However, Na V 1.7
Nav1.8 mice have significantly reduced behavioural responses to inflammatory mediators (formalin, complete Freund's adjuvant, carrageenan and nerve growth factor) when injected into the sole of the hind paw (Nassar et al. 2004 ) and impaired somatic noxious mechanosensation (Minett et al. 2012 (Minett et al. , 2014 . Thus far, only the deletion of Na V 1.7 in sympathetic and sensory (Wnt1-expressing) neurons and the global Na V 1.7 knock-out have been able to significantly reduce pain responses to a range of stimuli and recapitulate the human SCN9A-associated CIP phenotype (Gingras et al. 2014; Minett et al. 2014) . Recent studies also show that endogenous opioids contribute to pain insensitivity in both humans and mice lacking Na V 1.7, as the opioid antagonist naloxone reverses analgesia associated with the loss of Na V 1.7 expression (Minett et al. 2015) . This suggests that Na V 1.7 channel blockers alone may not replicate the analgesic phenotypes of Na V 1.7 null mutants, but may be potentiated with exogenous opioids. Na V 1.7-selective inhibitors are currently in clinical trial for different types of pain Yekkirala et al. 2017) .
In relation to visceral sensation, Na V 1.7 is highly abundant in human lumbar DRG, and is expressed in 100% of mouse colon-innervating thoracolumbar (T10-L1) DRG neurons, and in most colon-innervating lumbosacral (L5-S1) DRG neurons (Chang et al. 2018; Hockley et al. 2017; Inserra et al. 2017) (Table 1) . Accordingly, Na V 1.7 constitutes the most prevalent TTX-S isoform within colon-innervating DRG neurons. It is of interest to note that 'paroxysmal extreme pain disorder' , caused by the human gain of function SCN9A mutation, was originally called 'familial rectal pain syndrome'. As the name implies, this disorder is characterised by excruciating rectal and abdominal pain commonly associated with defecation (Fertleman et al. 2006) , suggesting a key role for Na V 1.7 in visceral pain. Moreover, pain perception in a subset of patients with interstitial cystitis/bladder pain syndrome (IC/BPS) is shown to correlate with a polymorphism in SCN9A (Reeder et al. 2013) . IC/BPS patients treated with a bladder infiltration of neosaxitoxin, a blocker of TTX-S Na V channels, resulted in significant analgesia and reduced bladder overactivity for 90 days after the treatment (Manriquez et al. 2015) . Normal physiological function of the bladder, however, appears to be independent of Na V 1.7, as SCN9A-associated CIP individuals have normal bladder control, and no increased incidence of urinary infections, incontinence, or retention (Cox et al. 2006) .
Despite these studies, the initial promise of Na V 1.7's contribution to visceral pain is somewhat tempered by experimental studies showing that Na V 1.7 Nav1.8 mice exhibit normal nocifensive responses to intracolonic administration of capsaicin (TRPV1 agonist) and mustard oil (TRPA1 agonist), indicating that Na V 1.7 is not crucial for acute visceral pain signalling (Hockley et al. 2017) . Low-threshold stretch-sensitive pelvic afferents are unaffected by the Na V 1.7 antagonist ProTX-II (Feng et al. 2015) (Table 2) . Similarly, ex vivo extracellular recordings of mesenteric afferents from resected human appendices show that peak firing before and after exposure to a novel Na V 1.7-selective antagonist, PF-5198007, is unchanged during repeat noxious ramp distensions (Hockley et al. 2017) . Afferent responses in mouse ex vivo colorectal recordings are attenuated by application of TTX (Feng et al. 2015) , indicating that TTX-S channels other than Na V 1.7 may be important in responding to innocuous and noxious mechanical stimuli. Accordingly, intracolonic co-administration of TTX and P-CTX-1 did not significantly alter the pain response induced by P-CTX-1 (Inserra et al. 2017) .
Ex vivo extracellular recordings of splanchnic nerve activity from the distal colon of Na V 1.7 Nav1.8 mice show no difference in peak firing between Na V 1.7 Nav1.8 and littermate control afferents in the physiological and supraphysiological pressure range (0-80 mmHg) (Hockley et al. 2017) . However, significantly less action potential firing in afferents from Na V 1.7 Nav1.8 mice at distension pressures in the supramaximal range (80-145 mmHg) is observed, suggesting that Na V 1.7 in Na V 1.8-positive colonic afferent neurons may be involved in transducing non-physiological extremes of pressure. This may be important and more relevant to chronic visceral pain states, when splanchnic afferents show mechanical hypersensitivity and decreased activation thresholds to mechanical stimuli (Hughes et al. 2009; Castro et al. 2013 Castro et al. , 2017 de Araujo et al. 2014; Osteen et al. 2016) . In the bladder, Na V 1.7 Nav1.8 mice have comparable levels of referred hyperalgesia in an acute cyclophosphamide-induced cystitis model compared to littermates (Hockley et al. 2017) . Overall, these findings suggest that Na V 1.7 has a role in mediating acute inflammatory pain in somatic but not visceral pathways. While studies on visceral nociception using Na V 1.7 Nav1.8 mice have provided valuable insight, replication of these studies in mice with sensory neuron-specific deletion of Na V 1.7 (e.g. Na V 1.7 Advill ) will be beneficial to strengthen conclusions concerning Na V 1.7 in visceral pain signalling.
Diseases that have a significant visceral pain component are commonly chronic and have unmet needs in terms of clinical treatment. Therefore, further investigations into the role of Na V 1.7 in long term and chronic visceral pain models, which are more clinically relevant to pathological chronic visceral pain states, are critical. For example, significant up-regulation of Na V 1.7 mRNA occurs 4 weeks after induction of colitis in colon-innervating DRG (L6-S1) neurons (Campaniello et al. 2016) . Similarly, rats with streptozotocin-induced diabetes show hypersensitivity to colonic distension, which corresponds with the up-regulation of Na V 1.7 protein in thoracolumbar (T13-L2) DRG neurons 4 weeks post-induction (Hu et al. 2016) . In support of these findings, rat neonatal colitis-induced visceral hypersensitivity induces up-regulation of Na V 1.7 protein levels in DRG from higher spinal levels (T13-L2), but not lower spinal levels (L4-L5) at 6 weeks post-colitis compared to control animals (Qu et al. 2013) . Taken together, these findings suggest that Na V 1.7 may have an acquired role during chronic visceral pain states. It is well documented that inflammation, tissue damage and healing of visceral organs can induce structural, synaptic or intrinsic neuroplasticity, altering neuronal and gastrointestinal function in the long term (Brierley & Linden, 2014) . For example, rectal samples from patients with physiologically characterised rectal hypersensitivity show significantly increased numbers of Na V 1.7-immunoreactive nerve fibres in the mucosal, submucosal and muscle layers compared to control tissues (Yiangou et al. 2007) . In addition to these findings, changes in the ratios of Na V 1.7 to a pan-neuronal structural marker, PGP9.5, indicate that increased Na V 1.7 expression and nerve sprouting occurs in rectal mucosa, which may contribute to enhanced sensitivity in these patients (Yiangou et al. 2007) .
Overall, the role of Na V 1.7 in pain sensation is complicated, and species differences in expression, assumed translatability of isoform-compound interaction, and effects of Na V knock-out on other genes may confound overall conclusions. Furthermore, few studies using human tissue have been completed, and healthy tissue is often obtained from patients with colonic or rectal carcinoma (Yiangou et al. 2007; Hetz et al. 2014; Hockley et al. 2017) . In addition to species-dependent differences in tissue distributions (Table 1) , there are also differences in relative isoform distributions, for example, Na V 1.7 is the most abundant isoform in human lumbar DRG, whereas Na V 1.8 is more abundant in mouse (Chang et al. 2018 ). Na V 1.7 isoforms from different species can also have different compound selectivity in heterologous expression systems that should be carefully considered during experimental design. For example, J Physiol 596.5 human, monkey, dog and mouse Na V 1.7 isoforms were found to be largely insensitive to a small molecule inhibitor of Na V 1.1/Na V 1.3 (ICA-121431) and potently inhibited by a small molecule inhibitor of Na V 1.7 (PF-04856264), whereas rat Na V 1.7 was potently inhibited by ICA-121431, but largely insensitive to PF-04856264 (McCormack et al. 2013) . A ProTxII analogue, JNJ63955918, on the other hand was equipotent at human and rat Na V 1.7 (Flinspach et al. 2017) . Single cell studies have shown that Na V channel expression is heterologous across cells, and there is high co-localisation of Na V 1.7 with Na V 1.6, Na V 1.8 and Na V 1.9 in colon-innervating thoracolumbar and lumbosacral neurons in mice (Hockley et al. 2017) . However, functional relationships of co-expression and investigations of redundancy between Na V channels are unclear. In knock-out models, deletion of one Na V gene can lead to a change in expression levels of over 190 genes (Minett et al. 2015) . Studies investigating Na V channel contribution to pain signalling using knock-out models or pharmacological modification may benefit from collecting data on regulation of other Na V family genes and auxiliary β-subunits in parallel, and other key genes where possible. Furthermore, inducible knock-out models offer the advantage of normal development and being able to compare Na V channel contribution preand post-induction of visceral hypersensitivity in the adult, thereby increasing therapeutic potential of these findings.
Na V 1.8 Na V 1.8 mediates slowly inactivating TTX-R Na + currents and carries the majority of the current underlying the upstroke of the action potential in nociceptive neurons. Hence, they are considered to play an important role in action potential electrogenesis (Renganathan et al. 2001) . Na V 1.8-null mice display reduced sensitivity to noxious mechanical stimuli (tail pressure) and noxious thermal stimuli (radiant heat), but normal sensitivity to acute noxious colonic distension by isotonic saline and intraperitoneal acetylcholine (Akopian et al. 1999; Laird et al. 2002) . Na V 1.8 is the most abundant isoform expressed in mouse lumbar DRG (Chang et al. 2018) , and is prevalently expressed in thoracolumbar (96%) and lumbosacral (91%) colonic sensory DRG neurons, with almost complete co-expression with Na V 1.7 (Hockley et al. 2017) . Consistent with this, knock-down of Na V 1.8 in DRG neurons results in action potentials with reduced peak amplitude and slower rise times, but similar baseline excitability (Renganathan et al. 2001; Hillsley et al. 2006) . Similarly, A-803467, a selective Na V 1.8 antagonist, does not significantly affect the frequency of action potential firing from low-threshold mechanosensitive colonic afferent nerve endings (Feng et al. 2015) . Together, these data seem to suggest that Na V 1.8 channels do play a major role in mediating visceral sensations and pain under physiological conditions. Na V 1.8 channels also have a major role in visceral signalling under pathophysiological conditions. Several studies support increased expression of Na V 1.8 protein in colon-innervating sensory DRG neurons in murine models of visceral hypersensitivity (Beyak et al. 2004; Hillsley et al. 2006; King et al. 2009; Qu et al. 2013; Hu et al. 2013a,b; Inserra et al. 2017; Lin et al. 2017) ( Table 2) . In most studies, increased channel expression correlates with enhanced TTX-R Na + current density in colon-innervating DRG neurons in vitro, and with visceral hypersensitivity in vivo, as the visceromotor response to noxious colonic distension in rats is significantly reduced following intraperitoneal administration of the Na V 1.8-specific antagonist A-803467 (Jarvis et al. 2007) . Similarly, colonic co-administration of A-803467 with P-CTX-1 significantly reduces P-CTX-1-induced nocifensive behaviours in mice (Inserra et al. 2017) . These findings are consistent with studies in Na V 1.8-null mice, which do not develop visceral hypersensitivity after intracolonic administration of sensitising agents such as capsaicin (TRPV1 agonist) and mustard oil (TRPA1 agonist). Furthermore, unlike their wild-type littermates, DRG neurons from Na V 1.8-null mice do not display enhanced neuronal hyperexcitability following intestinal infection with Nippostrongylus brasiliensis (Laird et al. 2002; Hillsley et al. 2006) .
Inflammatory mediators acting via GPCRs are powerful modulators of Na V 1.8 currents, and are believed to underlie increased excitability of nociceptive DRG neurons and associated hyperalgesia (Beyak et al. 2004) . In this regard, colon-innervating DRG neurons incubated with supernatant from colonic biopsies from patients with active ulcerative colitis (a chronic inflammatory bowel disease) show increased action potential discharge and enhanced Na V 1.8 currents (Ibeakanma & Vanner, 2010) . These effects were replicated by incubation with tumour necrosis factor α (TNFα), whose levels are enhanced in the ulcerative colitis supernatant. Similar sensitising effects have been reported for prostaglandin E2 (PGE2), adenosine, serotonin (5-HT), ATP, as well as nerve growth factor (NGF), which may persist during and possibly after the inflammation as a result of increased expression of Na V 1.8 channels (Gold, 1999; Gold et al. 2002; Beyak et al. 2004) . Recent data, however, indicate that these effects are not limited to inflammatory conditions, but may extend to non-inflammatory chronic pain states. Partial colonic obstruction is associated with an increase in Na V 1.8 mRNA expression, as well as enhanced TTX-R Na + currents and referred in vivo hyperalgesia, effects that were abolished by anti-NGF treatment (King et al. 2009; Ibeakanma & Vanner, 2010) .
Decreased TTX-R currents occur in bladderinnervating DRG neurons from T8 spinal transected rats (Yoshimura & deGroat, 1997) , which has since been attributed to a down-regulation of Na V 1.8 . This change is only seen in bladder-innervating DRG neurons, and is accompanied by an up-regulation of TTX-S current, which may also enhance the excitability of these afferent neurons. Knock-down of Na V 1.8 in rats at spinal levels L6-S1, known to contain the majority of bladder sensory terminals, does not have an effect on intercontraction intervals following cystometry with saline; however, intravesical acetic acid-induced hyper-reflexia is attenuated in knock-down rats (Yoshimura et al. 2001 ). Na V 1.8-null mice develop normal pain and inflammatory responses during cyclophosphamide-induced cystitis compared to littermates (Laird et al. 2002) , and pain behaviours are sustained in rats with cyclophosphamide-induced cystitis following intraperitoneal administration of A-803467 (Jarvis et al. 2007) .
Cross-organ sensitisation of the gastrointestinal and lower urinary tract is evident clinically and in animal models (Malykhina et al. 2004 Lei & Malykhina, 2012) , highlighting the importance of understanding the mechanisms of viscero-visceral crosstalk. Several studies report increases in TTX-resistant Na + current in bladder-innervating DRG neurons following colitis, implicating some involvement of TTX-R channels in bladder pain as a consequence of gastrointestinal tract inflammation. C-fibre bladder-innervating DRG neurons, involved in the transduction of noxious stimuli signalling (Fowler et al. 2008) , in the majority express TTX-R currents (Yoshimura & deGroat, 1997) . Collectively, experimental findings to date indicate that Na V 1.8 is not crucial for visceral pain signalling from the bladder in response to several noxious stimuli, but it may have an important role during referred hyperalgesia and in response to certain irritants.
Na V 1.9
Several human Na V 1.9 channelopathies are associated with congenital episodic pain syndromes, painful neuropathy, and an insensitivity to pain (Huang et al. 2014 . Na V 1.9 channels are preferentially expressed in small-diameter nociceptors (Dib-Hajj et al. 1998; Tate et al. 1998) , and mediate ultraslow or persistent TTX-R Na + currents. Due to their kinetic properties, Na V 1.9 channels are unlikely to contribute to action potential generation, but instead regulate neuronal excitability by setting the resting membrane potential closer to threshold (Dib-Hajj et al. 1998 , 2002 Tate et al. 1998) . In colonic afferents, action potential firing in response to colonic ramp distension is reduced in Na V 1.9 −/− mice, and accompanied by a run-down of responses to repeated phasic distension (Hockley et al. 2014) . Similar to Na V 1.8 channels, several studies indicate that Na V 1.9 currents can be enhanced via GPCRs (Maingret et al. 2008; Ostman et al. 2008; Vanoye et al. 2013; Hockley et al. 2016b) . Colonic afferent excitatory responses to the application of multiple inflammatory mediators (applied at once, either in the form of supernatants from chronically inflamed human bowel or as an experimental inflammatory soup containing ATP, PGE2, bradykinin, histamine and 5-HT) are significantly reduced in visceral afferents from Na V 1.9 −/− mice (Hockley et al. 2014 (Hockley et al. , 2016a (Table 2 ). Na V 1.9 −/− mice have similar baseline visceromotor responses to colonic distension to wild-type littermates, but reduced visceral hypersensitivity in vivo after colonic inflammation induced by activation of toll-like receptor 7 (Martinez & Melgar, 2008) . Neuronal hyperexcitability following Nippostrongylus bransiliensis infection is unchanged in Na V 1.9 −/− mice compared to wild-type littermates, reporting similar action potential characteristics and excitability of colon-innervating DRG neurons (Hillsley et al. 2006) . Likewise, others do not see changes in Na V 1.9 protein expression in colon-innervating DRG neurons, nor differences in either the numbers of neurons expressing persistent TTX-R (Na V 1.9) currents or the magnitude of these currents in acute TNBS-induced colitis (Beyak et al. 2004; King et al. 2009 ). It is unclear whether these discrepancies in the contribution of Na V 1.9 to neuronal (hyper)excitability relates to differences in knock-out constructs and mice strains, or to differences in the inflammatory insult studied. The latter may be of considerable importance as inflammatory mediators such as bradykinin, ATP, histamine, PGE2 and noradrenaline (norepinephrine), potentiate Na V 1.9 channel activity when applied conjointly, but fail to modulate Na V 1.9 currents when applied separately (Maingret et al. 2008) . Na V 1.9 channels are also present in myenteric plexus neurons in human, mouse, rat and guinea-pig (Rugiero et al. 2003; Padilla et al. 2007; Copel et al. 2009; Osorio et al. 2014) pointing towards an additional role in intestinal motor function. In line with this, colonic migrating motor complex patterns are altered in Na V 1.9 −/− mice (Copel et al. 2013) . Moreover, expression of Na V 1.9 channels is decreased in submucosal and myenteric plexus neurons (most likely intrinsic primary afferent neurons) in Hirschsprung's disease (O'Donnell et al. 2016) . Interestingly, these findings apply not only to aganglionic bowel sections, but in some patients extend to those sections containing normal ganglia numbers, which could explain some of the post-surgery bowel dysmotility issues frequently encountered by these patients (O'Donnell et al. 2016) . Conversely, a gain-of-function mutation (L811P) in the Na V 1.9 gene, SCN11A, identified in three unrelated individuals with congenital insensitivity to pain, is associated with severe gastrointestinal dysmotility, including alternating episodes of diarrhoea and constipation (Leipold et al. 2013; Woods et al. 2015) . In contrast, other gain-of-function mutations are predominantly linked to chronic pain syndromes such as autosomal-dominant episodic pain and small fibre neuropathy Huang et al. 2014; Han et al. 2015) .
No difference is observed in basal urodynamics between wild-type and Na V 1.9 −/− mice; however, the change of urodynamic parameters associated with cyclophosphamide-induced cystitis is absent in Na V 1.9 −/− mice, as well as attenuation of PGE2-induced afferent excitability during bladder distension (Ritter et al. 2009 ). It remains to be investigated whether this involvement of Na V 1.9 in bladder nociception is due to functional up-regulation of Na V 1.9 in bladder afferents, or whether Na V 1.9 has a role in central processing of bladder nociceptive pathways.
Conclusion
Recent findings highlight the diversity in expression patterns of Na V isoforms in abdominal visceral organs. This diversity extends across neurons (enteric, extrinsic sensory DRG innervating the intestine or bladder) and non-neuronal cells (intestinal enterochromaffin cells, intestinal smooth muscle cells, and interstitial cells of Cajal). Na V channels have a range of functions in health and disease and we are only now, with the development of novel pharmacological and genetic tools, beginning to unpick their complex physiological and pathophysiological interactions. Na V 1.1, Na V 1.6, Na V 1.8 and Na V 1.9, contribute to visceral hypersensitivity, particularly within colonic pathways, and respond to inflammatory mediators in pathophysiological models (Fig. 1) .
Whilst Na V 1.3 contributes to enterochromaffin cell function and Na V 1.5 contributes to intestinal smooth muscle cells and interstitial cells of Cajal function, there is currently no determined function in visceral afferents for Na V 1.2, Na V 1.3, Na V 1.4 or Na V 1.5, despite significant mRNA expression of Na V 1.2 and Na V 1.5 in visceral afferent pathways. Na V 1.7 is one of the most extensively expressed and studied Na V channels, but a role in visceral pain, like that attributed to Na V 1.7 in somatic pain studies is currently unclear. Although many of these Na V channels have been investigated under physiological conditions or in models of acute pain, chronic visceral pain models are necessary for the determination of a precise role in long term pathological visceral pain. Future studies would benefit from the further development of novel, specific agonists and antagonists, as we have seen with recent advances in the role of Na V 1.1 in mechanical pain. Likewise, selective Na V modulators with low systemic uptake for in vivo studies will advance our understanding of Na V channels in visceral pain signalling and the suitability of targeting Na V channels in the treatment of pain originating in the distal gut and bladder.
